Brought to you by 
Genentech gets license to Xencor's XmAb technology
03 Jan 2005
Executive Summary
Xencor (cancer, inflammation, and autoimmune disorders) has given Genentech an exclusive worldwide license to use its XmAb technology to develop and market cancer and autoimmune antibody therapeutics that target CD20 and Her2, plus another undisclosed antigen.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genentech gets license to Xencor's XmAb technology
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice